Literature DB >> 18270736

Effects of antiepileptic drug therapy on vitamin D status and biochemical markers of bone turnover in children with epilepsy.

Sina Nettekoven1, Alexander Ströhle, Birgit Trunz, Maike Wolters, Susanne Hoffmann, Rüdiger Horn, Martin Steinert, Georg Brabant, Ralf Lichtinghagen, Hans-Jürgen Welkoborsky, Ingrid Tuxhorn, Andreas Hahn.   

Abstract

Reports of decreased serum 25-hydroxyvitamin D (25-OHD) and altered bone metabolism associated with antiepileptic drug (AED) treatment are inconsistent and predominantly restricted to adults. In this cross-sectional observational study, the aim was to evaluate the influence of AED treatment on vitamin D status and markers of bone turnover in children with epilepsy. In 38 children taking AEDs and 44 healthy control subjects, blood samples were collected to determine the levels of serum 25-OHD, intact parathyroid hormone (iPTH), calcium (Ca), phosphate (P), bone alkaline phosphatase (BAP), osteocalcin (OC) and C terminal telopeptide of type I collagen (ICTP). More than 75% of the patients were vitamin D deficient (serum 25-OHD<20 ng/mL) and 21% of the patients had an insufficient vitamin D status (serum 25-OHD=20-30 ng/mL). In the patients, the serum levels of OC (p = 0.002) and BAP (p < 0.001) were significantly increased, but ICTP (p = 0.002) concentrations were significantly decreased compared with the control group. When patients where divided into two groups according to their medication (mono- or polytherapy), significantly lower 25-OHD (p = 0.038) and ICTP (p = 0.005) levels and elevated BAP (p = 0.023) concentrations were found in patients under polytherapy. An association between 25-OHD and the measured bone markers could not be determined. Our results indicate that the prevalence of vitamin D deficiency in epilepsy patients under AED treatment is high, especially under polytherapy, and alteration markers of bone formation and resorption suggests an accelerated skeletal turnover. The routine monitoring of serum 25-OHD and vitamin D supplementation on an individual basis should be considered.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18270736     DOI: 10.1007/s00431-008-0672-7

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  74 in total

1.  Pathophysiology of bone loss in patients receiving anticonvulsant therapy.

Authors:  Lorraine A Fitzpatrick
Journal:  Epilepsy Behav       Date:  2004-02       Impact factor: 2.937

2.  Early and persistent increase in serum lipoprotein (a) concentrations in epileptic children treated with carbamazepine and sodium valproate monotherapy.

Authors:  Konstantinos A Voudris; Achilleas Attilakos; Eustathia Katsarou; Antonios Drakatos; Stamatia Dimou; Sotiria Mastroyianni; Angeliki Skardoutsou; Alexia Prassouli; Anastasia Garoufi
Journal:  Epilepsy Res       Date:  2006-06-15       Impact factor: 3.045

3.  Bone mineral density and serum levels of 25 OH vitamin D in chronic users of antiepileptic drugs.

Authors:  Carolina A M Kulak; Victória Z C Borba; John P Bilezikian; Carlos E Silvado; Luciano de Paola; César L Boguszewski
Journal:  Arq Neuropsiquiatr       Date:  2004-12-15       Impact factor: 1.420

4.  Effect of antiepileptic drugs on bone mineral density in children between ages 6 and 12 years.

Authors:  G Kafali; T Erselcan; F Tanzer
Journal:  Clin Pediatr (Phila)       Date:  1999-02       Impact factor: 1.168

5.  Vitamin status in patients on chronic anticonvulsant therapy.

Authors:  K H Krause; P Berlit; J P Bonjour; H Schmidt-Gayk; B Schellenberg; J Gillen
Journal:  Int J Vitam Nutr Res       Date:  1982       Impact factor: 1.784

6.  Effects of usual nutrient intake and vitamin D status on markers of bone turnover in Swiss adolescents.

Authors:  F Ginty; C Cavadini; P-A Michaud; P Burckhardt; M Baumgartner; G-D Mishra; D V Barclay
Journal:  Eur J Clin Nutr       Date:  2004-09       Impact factor: 4.016

7.  Low plasma 25-hydroxyvitamin D and serum calcium levels in institutionalized epileptic subjects: associated risk factors, consequences and response to treatment with vitamin D.

Authors:  M W Davie; C E Emberson; D E Lawson; G E Roberts; J L Barnes; N D Barnes; A F Heeley
Journal:  Q J Med       Date:  1983

Review 8.  Why the optimal requirement for Vitamin D3 is probably much higher than what is officially recommended for adults.

Authors:  Reinhold Vieth
Journal:  J Steroid Biochem Mol Biol       Date:  2004-05       Impact factor: 4.292

9.  Evaluation of bone mineral density in children receiving antiepileptic drugs.

Authors:  R Akin; V Okutan; U Sarici; A Altunbas; E Gökçay
Journal:  Pediatr Neurol       Date:  1998-08       Impact factor: 3.372

10.  Effect of antiepileptic drugs on plasma lipids, lipoprotein (a), and liver enzymes.

Authors:  Fatma Mujgan Sonmez; Ercan Demir; Asim Orem; Sermet Yildirmis; Fazil Orhan; Adnan Aslan; Murat Topbas
Journal:  J Child Neurol       Date:  2006-01       Impact factor: 1.987

View more
  21 in total

1.  Vitamin D deficiency is prevalent in girls and women with Rett syndrome.

Authors:  Kathleen J Motil; Judy O Barrish; Jane Lane; Suzanne P Geerts; Fran Annese; Lauren McNair; Alan K Percy; Steven A Skinner; Jeffrey L Neul; Daniel G Glaze
Journal:  J Pediatr Gastroenterol Nutr       Date:  2011-11       Impact factor: 2.839

2.  The use of natural health products by paediatric patients in respite care.

Authors:  Audrey Beringer; Régis Vaillancourt; Gilda Villarreal; Christina Vadeboncoeur
Journal:  Paediatr Child Health       Date:  2015 Jan-Feb       Impact factor: 2.253

Review 3.  Effects of antiepileptic drugs on bone mineral density and bone metabolism in children: a meta-analysis.

Authors:  Ying Zhang; Yu-xin Zheng; Jun-ming Zhu; Jian-min Zhang; Zhe Zheng
Journal:  J Zhejiang Univ Sci B       Date:  2015-07       Impact factor: 3.066

4.  Treatment of epilepsy to optimize bone health.

Authors:  Alison M Pack
Journal:  Curr Treat Options Neurol       Date:  2011-08       Impact factor: 3.598

5.  Bone mass in Rett syndrome: association with clinical parameters and MECP2 mutations.

Authors:  Jay R Shapiro; Genila Bibat; Girish Hiremath; Mary E Blue; Shilpa Hundalani; Theodore Yablonski; Aditi Kantipuly; Charles Rohde; Michael Johnston; Sakkubai Naidu
Journal:  Pediatr Res       Date:  2010-11       Impact factor: 3.756

6.  Bone mineral density and vitamin D status in children with epilepsy, cerebral palsy, and cerebral palsy with epilepsy.

Authors:  Ayse Tosun; Seda Erisen Karaca; Tolga Unuvar; Yakup Yurekli; Cigdem Yenisey; Imran Kurt Omurlu
Journal:  Childs Nerv Syst       Date:  2016-10-18       Impact factor: 1.475

7.  Vitamin D in epilepsy: vitamin D levels in epilepsy patients, patients on antiepileptic drug polytherapy and drug-resistant epilepsy sufferers.

Authors:  S Nagarjunakonda; S Amalakanti; V Uppala; L Rajanala; S Athina
Journal:  Eur J Clin Nutr       Date:  2015-07-29       Impact factor: 4.016

Review 8.  Drug-vitamin D interactions: a systematic review of the literature.

Authors:  Kim Robien; Sarah J Oppeneer; Julia A Kelly; Jill M Hamilton-Reeves
Journal:  Nutr Clin Pract       Date:  2013-01-10       Impact factor: 3.080

9.  Effects of carbamazepine on serum parathormone, 25- hydroxyvitamin D, bone specific alkaline phosphatase, C-telopeptide, and osteocalcin levels in healthy rats.

Authors:  Hale Maral Kir; Sebnem Garip; Deniz Sahin; Berrin Öztaş
Journal:  Bosn J Basic Med Sci       Date:  2012-11       Impact factor: 3.363

10.  Vitamin D deficiency in children with epilepsy: Do we need to detect and treat it?

Authors:  Pooja Harijan; Arif Khan; Nahin Hussain
Journal:  J Pediatr Neurosci       Date:  2013-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.